the value of in-vitro diagnostics
DESCRIPTION
Forum “For Healthy Life” December 9-10, 2013, Moscow. The Value Of In-vitro Diagnostics. Healthcare challenges in the 21 st century for governments & hospitals & how in-vitro diagnostics can contribute to overcoming these. Regina Kloss-Wolf - PowerPoint PPT PresentationTRANSCRIPT
The Value Of In-vitro DiagnosticsHealthcare challenges in the 21st century for governments& hospitals & how in-vitro diagnostics can contributeto overcoming these
Regina Kloss-WolfDirector Global Strategic Health Initiatives, Abbott Laboratories
Forum “For Healthy Life”December 9-10, 2013, Moscow
Company Confidential © 2013 Abbott
The Healthcare World In The 21st Century:Having To Do More With Less
2
EconomicReality:
Decreased healthcare
budget
HealthcareReality:
Increasedhealthcare demand
Challenge #1
Ageingpopulation
Challenge #2
Riseof NCDs
Demographic change reinforces rise of NCDs
Healthcare reality: increased demand for
healthcare
Healthcare Reality - Challenge 1:Population Ageing
3Sources: United Nations, Population Facts, Population Ageing and the non-communicable diseases, April 2012, accessed 25 November 2013.United Nations, World Population Ageing 1950-2050, accessed 25 November 2013.
http://www.un.org/esa/population/publications/worldageing19502050/pdf/173russi.pdf
60+yrs
2000: 18%
2050: 37%
2025: 26%
Russia
Healthcare Reality - Challenge 2:Non Communicable Diseases - Key Facts
4
“Non Communicable diseases(chronic diseases) are not
passed from person to person.They are of long duration &generally slow progression”
NCDs cause more than36 million deaths worldwide
– 63% of all mortality
Between 70% & 80% ofEurope’s healthcare costsare spent on chronic care,
amounting to €700bn
Early intervention mayenable early detection &
hence contribute to cost-reduction
Company Confidential © 2013 Abbott
Sources: WHO, factsheet on Chronic Diseases, accessed 25 November 2013. WHO, factsheet on Noncommunicable diseases, accessed 25 November 2013.EPHA, Extend healthy years by tackling chronic diseases in a life-course approach, accessed 25 November 2013.
Healthcare Reality - Challenge 2Rise Of Cardio Vascular Diseases & Associated Costs
5
2008 2010 2030
Sources; AIHW, Why are mortality data important?, accessed 25 November 2013. World Economic Forum, Non-communicable Diseases to cost $47 trillion by 2030, New Study Released Today, accessed 25 November 2013. World Heart Federation, The cost of CVD, accessed 25 November 2013. WHO, factsheet on Cardiovascular Diseases,, accessed 25 November 2013.
Company Confidential © 2013 Abbott
2008 2010 2030
CVDS
17.3 million people dying of CVDs
Cost of CVDs: $863bn
CVDs 23.3 million of people dying of CVDs
Cost of CVDs:$1,044bn
Healthcare Reality - Challenge 2Rise Of Cardio Vascular Diseases & Associated Costs
6
20122012
NCDs account for 90% of all deaths
CVDs account for 57% of all deaths
Russia
2006-2009
NCDs
Cost of CVDs: 3% of GDP
RUR
CVDs
Source: Petrukhin IS, Lunina EY. Cardiovascular disease risk factors and mortality in Russia: challenges and barriers. Public Health Reviews. 2012;33:436-49Company Confidential
© 2013 Abbott
So What Does The Rise Of NCDs Mean?
7
The worldwide rise of chronicNon Communicable Diseases:
a slow-motion catastrophe
Margaret ChanWHO Director General
Company Confidential © 2013 Abbott
8
Increasing use of Clinical Guidelines and Quality Measurements Globally
Clinical outcomes
Cost-effectiveness
Mortalityrates
Hospital bed occupancy
rate
Cost per discharge
Length of stay
Unplanned readmission
Average waiting time for patient
How Do IVDs Fit Into This ?
Company Confidential © 2013 Abbott
9
IVDCase
Studies
How can IVDs contribute to overcoming this
challenge?
Company Confidential © 2013 Abbott
The Diagnostics Paradox:Recognised Important Role, but Low Investment
10
Early diagnosis & treatment stops NCDs progressing into costly, crippling
complications & premature death
NCD Alliance
10
Medical decisions are based on IVDs
70%
Healthcare budget spent on IVD’s2%
Sources: NCD Alliance, Discussion Paper No. 3 Geneva 2011, accessed 25 November 2013.EDMA answer to the European Commission consultation on Community Action on Health Services, 31 January 2007, p.2
Company Confidential © 2013 Abbott
IVDs: One Of The Key Tools In Diagnostics
11Company Confidential © 2013 Abbott
Monitoring of prescribed treatments
Disease prevention& Population screening
Assessmentof medical
interventions
Diagnosis, treatment selection
& Prognosis
In Vitro Diagnostics are usedalongside the healthcare pathway
Case1: Early diagnosis of heart failure and differentiation from other diseases causing dyspnoea
Company Confidential © 2013 Abbott
The challengeManagement of patients
with acute Dyspnoea
The impacton quality
measurements
Biomarker helpsto diagnose
congestive heart failure
BNP(B-type Natriuretic
Peptide)
Cost per discharge
HF is the most frequent diagnosis associated with
30 day readmission30
Treatmentcost
Mortality
Cost per patient$-1.854
Admission rate-10%
Length of stay-2.2
12
Case 2: Taking The Right Decision In Case Of Heart Attack In Patients With Acute Chest Pain
Company Confidential © 2013 Abbott
The challengeCorrect triaging
The impacton quality
measurements
Earlier triage of patients, already
after 2-4 hrs.with hs Troponin
vs. 6-12 hrs.
hs Troponin
Cost per discharge
Only 7-20% of patients who present with chest pain in the
ED are confirmed for diagnosis of myocardial
infarct
7-20% More confident rule out
for up to 40 % with suspected acute coronary
syndrome40%
Waiting times
Waiting times
Cost per discharge
Better allocation
13
14
Conclusion
• The burden of the ageing world population and NCDs will continue to rise.
• IVDs play an important role in optimizing care and minimizing cost
• IVDs are critical to the successful implementation of clinical guidelines and quality measures.
Company Confidential © 2013 Abbott